The results of a pre-specified exploratory analysis of the DANFLU-2 study indicate that the administration of a high-dose inactivated influenza vaccine could provide additional protection in patients with cardiovascular disease. The DANFLU-2 study was conducted in Denmark in the period 2022-2025 over three consecutive influenza seasons.
Dieser Inhalt ist nur für Benutzer der Gruppe: Medizinische Fachperson zugänglich
Jetzt beitreten
Jetzt beitreten
Already a member? Log in here
